Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 3/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.56 |
| ▸ | CDK2 | P24941 | 12/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 12/20 | 0.56 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294933 | 0.97 | AURKB (0.56) | AURKBSRCGSK3BCCNA2CDK2 | |
| SCHEMBL10294845 | 0.90 | AURKB (0.55) | AURKBSRCGSK3BCCNA2CDK2 | |
| SCHEMBL10294760 | 0.88 | AURKB (0.47) | AURKBSRCGSK3BCCNA2CDK2 | |
| SCHEMBL10294757 | 0.88 | AURKB (0.47) | AURKBSRCGSK3BCCNA2CDK2 | |
| SCHEMBL10294768 | 0.87 | AURKB (0.67) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL10295003 | 0.87 | AURKB (0.47) | AURKBSRCGSK3BCCNA2CDK2 | |
| SCHEMBL10294831 | 0.86 | AURKB (0.54) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL10295014 | 0.85 | AURKB (0.64) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL10294843 | 0.85 | AURKB (0.61) | AURKBSRCGSK3BAURKA | |
| SCHEMBL10294863 | 0.85 | AURKB (0.55) | AURKBSRCGSK3BCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2010144359-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | AURKB 3449/4885SRC 1662/4885GSK3B 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.